FindMyKOL
Clinical trialNCT07470853RecruitingPhase 1Interventional

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

SponsorWhitehawk Therapeutics, Inc.Enrollment265Endometrial CancerPROCPlatinum Resistant Ovarian Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Arkansas - Winthrop P. Rockefeller Cancer Institute

    Little Rock, Arkansas, United States

    Recruiting
  • Start - Los Angeles

    Los Angeles, California, United States

    Recruiting
  • Scri - Florida Cancer Specialists

    Sarasota, Florida, United States

    Recruiting
  • St. Francis Medical Center (osf Healthcare)

    Peoria, Illinois, United States

    Michelle Rowland, MD
    Recruiting
  • Karmanos Cancer Center

    Detroit, Michigan, United States

    Not, yet, recruiting
  • Start - Ny

    Long Island City, New York, United States

    Geraldine O'Sullivan-Coyne, MD
    Recruiting
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Not, yet, recruiting
  • Atrium Health - Wake Forest

    Charlotte, North Carolina, United States

    Not, yet, recruiting
  • Ohio State University Wexner Medical Center

    Columbus, Ohio, United States

    David O'Malley, MD
    Recruiting
  • Scri - Sydney Kimmel Cancer Center - Jefferson Health

    Philadelphia, Pennsylvania, United States

    Recruiting
  • Scri - Mary Crowley Cancer Research

    Dallas, Texas, United States

    Recruiting
  • Start Mountain

    Salt Lake City, Utah, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →HWK-016, MUCIN-16-targeted ADC
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Mar 2026
Primary completion
29 Feb 2028
Completion
29 Feb 2028
Last update posted
18 Aug 2026
Registered enrollment
265
Registry id
NCT07470853

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.